Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP202 for prevention of post-myocardial infarction cardiac remodelling
ACTRN12615000609550Phase 2Completed
- Sponsor
- Armaron Bio
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) and left ventricular remodelling comparing NP202 with Placebo (2 arms). Primary endpoint: Efficacy on left ventricular remodelling. Started Nov 2015; status: completed.
02
Drugs
NP202
03
Conditions
myocardial infarction (MI)left ventricular remodelling
Beyond the preview
Go deeper on ACTRN12615000609550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000609550.